Glimepiride
- Generic Name
- Glimepiride
- Brand Names
- Duetact, Tandemact
- Drug Type
- Small Molecule
- Chemical Formula
- C24H34N4O5S
- CAS Number
- 93479-97-1
- Unique Ingredient Identifier
- 6KY687524K
- Background
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure a...
- Indication
Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)
- Conditions
- Interventions
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 307
- Registration Number
- NCT01704261
Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)
- Conditions
- Interventions
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2015-01-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 42
- Registration Number
- NCT01703286
- Locations
- 🇩🇪
1218.105.001 Boehringer Ingelheim Investigational Site, Neuss, Germany
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2013-08-01
- Lead Sponsor
- Akros Pharma Inc.
- Target Recruit Count
- 325
- Registration Number
- NCT01699737
A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)
- Conditions
- Interventions
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 751
- Registration Number
- NCT01682759
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 299
- Registration Number
- NCT01678820
Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using "Biphase-Hyperglycemic Clamp"
- Conditions
- Interventions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 12
- Registration Number
- NCT01660386
- Locations
- 🇨🇳
Shanghai Jiao Tong University School of Medicine, Shanghai, China
A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2012-07-19
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 737
- Registration Number
- NCT01644500
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yong Kung City, Taiwan
The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)
- Conditions
- Interventions
- First Posted Date
- 2012-06-04
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Target Recruit Count
- 15
- Registration Number
- NCT01610934
- Locations
- 🇩🇰
Diabetes research Division, University Hospital Gentofte, Hellerup, Denmark
A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)
- Conditions
- Interventions
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 498
- Registration Number
- NCT01590771
Double Blind Comparative Study of TAK-875
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2013-04-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 80
- Registration Number
- NCT01585792
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.